Ed Arce’s Buy Rating on Arcturus Therapeutics Driven by Strategic Advancements and Strong Market Positioning
In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Arcturus Therapeutics (ARCT – Research Report), with a ...
Arcturus Therapeutics' SWOT analysis: mRNA innovator's stock faces pivotal year
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of ...
Arcturus: Downgrading As mRNA Promise Meets Market Reality
Arcturus Therapeutics Holdings Inc. stock is down 46% since Sept. 2023 coverage; mRNA sector faces headwinds with public ...
SEC Oil Fraud Case Gets Nod for Over $10 Million in Remedies
Oil and gas companies Arcturus Corp. and Aschere Energy LLC, along with founder Leon Ali Parvizian, must pay more than $10 ...
Arcturus Therapeutics to Present at Guggenheim Securities SMID Cap Biotech Conference
Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...
Hosted on MSN3d
BTIG Initiates Coverage of Arcturus Therapeutics Holdings (ARCT) with Buy Recommendation
Fintel reports that on January 28, 2025, BTIG initiated coverage of Arcturus Therapeutics Holdings (NasdaqGM:ARCT) with a Buy ...
Dallas Innovates3d
North Texas’ Skyven Inks $70M Agreement with France’s Kyotherm to Advance Industrial ‘Decarbonization’
The co-development and project finance agreement will accelerate deployment of Skyven's cutting-edge, "decarbonizing" ...
Demystifying Arcturus Therapeutics: Insights From 5 Analyst Reviews
In the assessment of 12-month price targets, analysts unveil insights for Arcturus Therapeutics, presenting an average target ...
Skyven Technologies Secures $70M Co-Development and Project Finance Agreement with Kyotherm to Accelerate Industrial Decarbonization
Skyven Technologies, a leader in emissions-free industrial steam, and Kyotherm, a renowned financier of renewable thermal ...
Arcturus Therapeutics (NASDAQ:ARCT) Now Covered by Analysts at BTIG Research
BTIG Research began coverage on shares of Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) in a research report issued on Tuesday, MarketBeat reports. The brokerage set a “buy” rating and a ...
Arcturus股票保持买入评级，剂量研究进行中
该公司的认可紧随Arcturus最近宣布两项针对其mRNA治疗项目的Phase 2多次递增剂量研究已开始给药。根据InvestingPro的公允价值分析，目前市值约5.17亿美元的Arcturus似乎被低估。
BTIG为Arcturus股票设定41美元目标价，看好其前景
周二，BTIG分析师开始对Arcturus Therapeutics (NASDAQ: ARCT )进行覆盖，给予"买入"评级，并设定41.00美元的目标价。该商业化阶段的生物技术公司以mRNA疗法和疫苗为重点，目前交易价格为16.49美元，市值4.47亿美元。根据 InvestingPro ...